Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per... Read More
